Why the babesiosis update matters only if it can change the business case
This update matters only if the babesiosis program can translate into a labeling expansion for ARAKODA, not just a better press cycle. 60 Degrees is still operating from a approximately $162 thousand quarterly revenue base, with about $76 thousand of gross profit and a net loss attributable to common shareholders of about $2.21 million in Q1. Current operations, therefore, do not fund the story.
What bulls are watching
Bulls are focused on timing. The company says enrollment is tracking ahead of schedule, and the minimum enrollment to support interim analysis is expected as soon as early July 2026. If that timeline holds and interim data support efficacy, investors get a reason to look beyond malaria prevention as the only near-term commercial anchor for the business.
What bears are watching
Bears have a straightforward counterargument: a trial headline is not yet a business. Babesiosis still needs to become a credible labeling bridge before it can change the investment case in a durable way.
Why the timing matters now
The next visible checkpoint is early July 2026. If institutions want exposure to a repricing event, the window is before that date, not after another quarterly loss report.
What changed: the calendar improved before the evidence stack did
What changed this week is the calendar, not the full evidence stack. The new trigger is that the first completed patient tested negative for babesiosis. That is not a final readout, but it is an early positive signal in the right direction. The remaining enrolled patients are still expected to complete the study between January and October 2026.
The hospitalization trial has to show efficacy first
The current hospitalization trial is an efficacy-first program: a randomized, double-blind, placebo-controlled trial evaluating tafenoquine in hospitalized babesiosis patients. If that study produces supportive efficacy data, it strengthens the case for a treatment indication tied to the ARAKODA asset.
The relapsing study is meant to reinforce the signal
The immunosuppressed relapsing program is a separate test case. Its purpose is to see whether the early signal holds in a harder-to-treat population. The negative result in the first completed patient is the kind of early data point bulls want to see, but it does not settle the labeling question on its own.
The core question is still whether prevention can expand into treatment
For now, 60 Degrees remains focused on the commercialization of ARAKODA for malaria prevention, while babesiosis development is intended to support future applications to expand ARAKODA labeling.
A treatment indication would matter because No U.S. Food and Drug Administration-approved treatment or vaccine exists for babesiosis. If the company can build a credible path from prevention to treatment, the story changes from a niche malaria product with a side program to a potential label expansion into an unmet-need space.
Where the uncertainty remains
That bridge is still unfinished. Even if early signals hold, the company still needs FDA engagement and a workable regulatory path through an sNDA process. Patient completions are expected between January and October 2026, so the timeline still allows for delay or mixed signals.
Funding is the real constraint in a company this small
The more important question this week is financing, not the science story alone. In a company this small, capital decides how much time there is and who bears the risk. The last public offering gave 60 Degrees about $5 million upfront, plus up to an additional $5 million if the short-term warrants are exercised. That can extend the runway to results, but it can also increase dilution.
That tension matters because management now says minimum enrollment to support interim analysis expected as soon as early July 2026. The clinical calendar is becoming clearer, but the financing structure still leaves open the question of what happens if the company needs more capital before the story is fully proven.
Shelf space changes the option set. 60 Degrees has a Form S-3 shelf available, which could provide a faster path back to public markets if needed. Bulls can view that as flexibility; bears can view it as an easier exit ramp. If operations still cannot fund the business, another raise remains a real possibility.
What to watch next
- Whether the July 2026 milestone stays on track
- Whether early microbiologic signals turn into efficacy data
- Whether the company can progress toward a labeling bridge without dilution overwhelming existing holders